Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S-(4-bromobenzyl)cysteine is a synthetic small molecule belonging to the class of L-cysteine-S-conjugates. Structurally, it features an L-cysteine backbone with a thioether linkage to a 4-bromobenzyl group at the sulfur atom. The compound exists as the (R)-enantiomer and is zwitterionic at physiological pH. Biologically, it acts as both a substrate and inhibitor for cysteine conjugate β-lyases—enzymes involved in xenobiotic metabolism. Upon enzymatic cleavage by β-lyase, it can generate reactive intermediates such as enethiolates that may alkylate DNA or proteins, suggesting potential genotoxicity. It is considered experimental and has not been approved for any therapeutic indication[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on S-(4-bromobenzyl)cysteine.